![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RNF38 |
Gene summary for RNF38 |
![]() |
Gene information | Species | Human | Gene symbol | RNF38 | Gene ID | 152006 |
Gene name | ring finger protein 38 | |
Gene Alias | RNF38 | |
Cytomap | 9p13.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9H0F5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
152006 | RNF38 | CCI_1 | Human | Cervix | CC | 8.17e-05 | 7.96e-01 | 0.528 |
152006 | RNF38 | CCI_2 | Human | Cervix | CC | 1.74e-10 | 1.09e+00 | 0.5249 |
152006 | RNF38 | CCI_3 | Human | Cervix | CC | 4.09e-12 | 8.65e-01 | 0.516 |
152006 | RNF38 | HTA11_3410_2000001011 | Human | Colorectum | AD | 7.09e-18 | -5.83e-01 | 0.0155 |
152006 | RNF38 | HTA11_83_2000001011 | Human | Colorectum | SER | 6.88e-03 | -1.88e-01 | -0.1526 |
152006 | RNF38 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.26e-03 | -4.16e-01 | 0.096 |
152006 | RNF38 | HTA11_8622_2000001021 | Human | Colorectum | SER | 3.84e-03 | -5.47e-01 | 0.0528 |
152006 | RNF38 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.30e-08 | -4.31e-01 | 0.0674 |
152006 | RNF38 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.83e-06 | -3.54e-01 | 0.294 |
152006 | RNF38 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.23e-03 | 7.39e-01 | 0.3487 |
152006 | RNF38 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 6.63e-06 | -2.94e-01 | 0.3859 |
152006 | RNF38 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 6.31e-05 | -5.46e-01 | 0.2585 |
152006 | RNF38 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.01e-17 | -4.81e-01 | 0.3005 |
152006 | RNF38 | A002-C-010 | Human | Colorectum | FAP | 7.39e-05 | -2.07e-01 | 0.242 |
152006 | RNF38 | A001-C-207 | Human | Colorectum | FAP | 3.31e-03 | -2.91e-01 | 0.1278 |
152006 | RNF38 | A015-C-203 | Human | Colorectum | FAP | 1.48e-36 | -5.09e-01 | -0.1294 |
152006 | RNF38 | A015-C-204 | Human | Colorectum | FAP | 4.62e-07 | -3.25e-01 | -0.0228 |
152006 | RNF38 | A014-C-040 | Human | Colorectum | FAP | 2.13e-04 | -3.84e-01 | -0.1184 |
152006 | RNF38 | A002-C-201 | Human | Colorectum | FAP | 9.49e-18 | -5.11e-01 | 0.0324 |
152006 | RNF38 | A002-C-203 | Human | Colorectum | FAP | 2.79e-09 | -2.86e-01 | 0.2786 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00451373 | Prostate | BPH | development of primary sexual characteristics | 58/3107 | 227/18723 | 3.67e-04 | 2.71e-03 | 58 |
GO:00075483 | Prostate | BPH | sex differentiation | 68/3107 | 276/18723 | 3.75e-04 | 2.76e-03 | 68 |
GO:006145816 | Prostate | Tumor | reproductive system development | 133/3246 | 427/18723 | 1.24e-12 | 1.15e-10 | 133 |
GO:004860815 | Prostate | Tumor | reproductive structure development | 131/3246 | 424/18723 | 3.48e-12 | 2.89e-10 | 131 |
GO:004666111 | Prostate | Tumor | male sex differentiation | 48/3246 | 165/18723 | 1.25e-04 | 1.16e-03 | 48 |
GO:000840612 | Prostate | Tumor | gonad development | 60/3246 | 221/18723 | 1.68e-04 | 1.50e-03 | 60 |
GO:000858411 | Prostate | Tumor | male gonad development | 42/3246 | 141/18723 | 1.83e-04 | 1.61e-03 | 42 |
GO:004654611 | Prostate | Tumor | development of primary male sexual characteristics | 42/3246 | 142/18723 | 2.17e-04 | 1.86e-03 | 42 |
GO:000754811 | Prostate | Tumor | sex differentiation | 71/3246 | 276/18723 | 2.70e-04 | 2.24e-03 | 71 |
GO:004513712 | Prostate | Tumor | development of primary sexual characteristics | 60/3246 | 227/18723 | 3.65e-04 | 2.86e-03 | 60 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RNF38 | SNV | Missense_Mutation | c.434A>G | p.His145Arg | p.H145R | Q9H0F5 | protein_coding | tolerated(0.8) | benign(0) | TCGA-B6-A0RT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
RNF38 | deletion | Frame_Shift_Del | novel | c.748delN | p.Ala250HisfsTer59 | p.A250Hfs*59 | Q9H0F5 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
RNF38 | SNV | Missense_Mutation | novel | c.1387N>C | p.Cys463Arg | p.C463R | Q9H0F5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RNF38 | SNV | Missense_Mutation | novel | c.1019N>T | p.Pro340Leu | p.P340L | Q9H0F5 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RNF38 | SNV | Missense_Mutation | novel | c.70G>C | p.Glu24Gln | p.E24Q | Q9H0F5 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.727) | TCGA-ZJ-AAXA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RNF38 | SNV | Missense_Mutation | c.574C>A | p.His192Asn | p.H192N | Q9H0F5 | protein_coding | deleterious_low_confidence(0) | benign(0.276) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
RNF38 | SNV | Missense_Mutation | novel | c.252N>A | p.Met84Ile | p.M84I | Q9H0F5 | protein_coding | tolerated(0.39) | benign(0.01) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RNF38 | SNV | Missense_Mutation | novel | c.1195N>T | p.Pro399Ser | p.P399S | Q9H0F5 | protein_coding | tolerated(0.13) | probably_damaging(0.999) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
RNF38 | SNV | Missense_Mutation | c.257N>T | p.Pro86Leu | p.P86L | Q9H0F5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RNF38 | SNV | Missense_Mutation | c.1324N>T | p.Asp442Tyr | p.D442Y | Q9H0F5 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |